DRAVP ID  DRAVPa2433

Peptide Name   Sequence 2 from Patent CN118161592A

Sequence  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA

Sequence Length  42

Source  Synthetic construct

Target Organism  SARS-CoV-2

Patent Type  Patent Application

Publication Date  2024-06-11

Patent No  CN118161592A

Family Info  CN 118161592 A

Patent Title  Glycopeptide compound for inhibiting SARS-CoV-2 virus infection and application thereof

Comment 

Abstract  The invention relates to the field of biological medicine, in particular to a glycopeptide compound for inhibiting SARS-CoV-2 virus infection. The glycopeptide compound disclosed by the invention comprises polypeptide and polysaccharide, wherein the polypeptide comprises a polypeptide P1 or a polypeptide P2, and the amino acid sequence of the polypeptide P1 is as shown in SEQ ID NO.1; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.1 through amino acid substitution, deletion or increase; the amino acid sequence of the polypeptide P2 is as shown in SEQ ID NO. 2; or a sequence which has more than 90% similarity with the sequence as shown in SEQ ID NO.2 through amino acid substitution, deletion or increase; the structural fragment of the polysaccharide comprises any one or more than two of xFuc-N1Gal-N1 (xFuc-N1) GlcNAc structural units, x is equal to 0 or 1, and N1 is equal to 1, 2, 3, 4 or 6. The glycopeptide compound can be combined with S protein of the novel coronavirus and heparin molecules on the surface of human cells, and host cells are protected from invasion of the novel coronavirus through competitive inhibition.